Medical oncologist and real-world data leader succeeds Miruna Sasu, whose leadership expanded COTA’s impact across life sciences.
A Leader Rooted in Both Medicine and Data
COTA, an oncology real-world data and analytics company, today announced that C.K. Wang, MD has been appointed Chief Executive Officer, effective immediately.
Dr. Wang has served as COTA’s Chief Medical Officer since 2020, where he played a central role in shaping the company’s medical strategy and ensuring the scientific rigor of its datasets. Over the past several years, he has:
- Led the development of COTA’s research services, helping partners design and execute high-impact studies.
- Oversaw the buildout of COTA’s quality management services to maintain the highest standards of data accuracy and completeness.
- Guided the creation of COTA’s regulatory consulting offerings, expanding how real-world data supports regulatory submissions.
- Led the expansion of COTA’s provider partner base, expanding COTA’s network across the US
- Served as Steering Committee Chair of the Clinical Research Data Sharing Alliance (CRDSA), advancing industry standards for responsible data sharing.
Dr. Wang’s appointment reflects a continued commitment to COTA’s mission: tackling complex cancers through deep, accurate, and high-quality oncology data.
“COTA’s mission has always been deeply personal to me,” said Dr. Wang. “As both a clinician and a data leader, I’ve seen how trusted, representative real-world data can accelerate discovery and improve patient outcomes. I’m honored to help guide the company and continue building on the strong foundation our team has created.”
About C.K. Wang, MD
A medical oncologist by training, Dr. Wang brings more than two decades of experience across clinical care, data science, and oncology innovation. Prior to joining COTA, he served as Acting Deputy Chief Health Officer for Oncology and Genomics at IBM Watson Health, where he led AI-driven oncology initiatives on a global basis.
Before transitioning to the data and technology sector, Dr. Wang practiced oncology in the Dallas–Fort Worth area, holding leadership roles including Managing Partner with Dallas Oncology Consultants, Director of Oncology with the Medical Clinics of North Texas, and Cancer Program Chairman with USMD Hospital at Arlington.
In 2024, FierceHealthcare named Dr. Wang one of the 10 Most Influential Minority Executives in Healthcare for his work promoting diversity and representativeness in oncology research, including among LGBTQ+ patients.
Recognizing Miruna Sasu’s Leadership
COTA also expresses gratitude to Miruna Sasu, who led the company through an important period of growth and transformation.
During her tenure as CEO, Miruna helped expand partnerships with leading life sciences organizations, strengthened the company’s data products and services, and solidified COTA’s position as a trusted voice in oncology real-world data. She recently returned to her roots in large pharma, joining Novartis as Chief Data Officer.
“Miruna’s vision and dedication have been instrumental in shaping who we are today,” said Dr.Wang. “She positioned COTA for continued growth in the years ahead, and we’re proud to see her talent and impact recognized by the broader life sciences community as she takes on her next role.”
Continuing the Mission
Under Dr. Wang’s leadership, COTA will continue to expand its high-quality oncology datasets and real-world evidence solutions for partners across research, clinical development, and regulatory functions.
The company remains focused on transforming cancer care through data that is clinically rich, representative, and trusted by researchers and clinicians alike.
“C.K. is a respected clinician and a trusted leader within COTA,” said Andrew Pecora, MD, Founder and Chairman of COTA. “He understands both the science and the mission, and he is deeply committed to advancing our work to improve outcomes for patients facing cancer.”